# A Study of NBL-012 in Healthy Chinese Subjects

> **NCT05259189** · PHASE1 · COMPLETED · sponsor: **NovaRock Biotherapeutics, Ltd** · enrollment: 52 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** NBL-012 Injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05259189
- **Lead sponsor:** NovaRock Biotherapeutics, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-01
- **Primary completion:** 2022-05-23
- **Final completion:** 2022-05-23
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05259189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05259189, "A Study of NBL-012 in Healthy Chinese Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05259189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*